A study to improve the diagnosis of bladder cancer (BladderPath Study)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Cancer type:
Status:
Phase:
This study is looking at using an MRI scan to diagnose bladder cancer that has grown into the muscle.
More about this trial
- how accurate MRI scans are at diagnosing invasive bladder
- if the scan reduces treatment waiting times for people with invasive bladder cancer
- if the scan avoids unnecessary surgery
Who can enter
You may be able to join this study if all of the following apply.
- are having tests for suspected bladder cancer
- have had a test to look inside the bladder and you now need to have TURBT
- are at least 18 years old
- are unable to or unwilling to have an MRI scan
- are unsuitable or unfit to have a TURBT
- have had bladder cancer in the past
- are pregnant or breastfeeding
Trial design
- the standard way of diagnosing bladder cancer (pathway 1)
- the newer way of diagnosing bladder cancer (pathway 2). This group is then divided into those who:
- probably don’t have cancer in the muscle (you have a standard TURBT)
- possibly have cancer in the muscle (you have an MRI of the bladder)
The standard way of diagnosing (pathway 1)
- a TURBT to remove the suspicious lesion
- a specialist doctor examining tissue samples to check for bladder cancer and if it has grown into the muscle wall
- an MRI scan if doctors predict there is cancer in the muscle
- a TURBT if doctors predict there isn’t cancer in the muscle
- chemotherapy
- radiotherapy
- surgery
Hospital visits
- blood samples
- urine sample
Side effects
No method of assessing bladder cancer is 100% accurate. For both groups, there is a risk of over or under treatment.
In the standard diagnosis group, there is a small risk that the initial TURBT can show that the tumour hadn’t grown into the muscle wall. But it had. This means these people don't have enough initial treatment or treatment is delayed.
In the newer way of diagnosing there is a small risk of over treatment. This means the scan over estimates the cancer is in the muscle layer of the bladder. So, you have might have treatment that you don’t need. Researchers haven’t done this type of study before. But they predict this might happen in under 5 out of every 100 people (5%).
Having an MRI scan is a safe test. There is a very small chance that you might have an allergic reaction to the contrast medium you have to show up your body organs more clearly. But the person doing the test will keep a close eye on you and treat any problems straight away.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Nick James
Supported by
University of Birmingham
NIHR Health Technology Assessment (HTA) programme
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040